Expert insight and analysis providing information directly relevant to cystic fibrosis care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Until the advent of highly effective CFTR modulator medications, cystic fibrosis was considered a pediatric disease, because most individuals did not survive into adulthood. Now, with more adults living with CF than children, priorities must change. In these interviews, we discuss what transitions to a longer life with CF entails: from pediatric to adult care; from the possibilities of motherhood and the need for family planning; from adulthood into older age and the infirmities common to all aging adults.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
23 Dec 2022
CF and Diet and Nutrition: The Changing Paradigm
Individuals with cystic fibrosis — adults as well infants and children — have long struggled to gain and maintain their weight. But how has the current widespread use of highly effective modulator treatments — HEMT — changed that situation? That’s the focus of this eCysticFibrosis Review Special Edition: CF and Nutrition and HEMT.
The first part of this program presented an evidence-based Expert Commentary on the current status of weight gain, obesity, and nutrition among people with CF by guest author Katie McDonald, PhD, MS, RDN, CSP, a clinical dietitian at Primary Children's Medical Center in Salt Lake City. The second part is a podcast interview, providing further in-depth discussions between Katie McDonald and three top CF nutrition experts.
Take our post-test (https://elit.dkbmed.com/issues/158/test) to claim CME credits.
Read this podcast's companion newsletter here (https://elit.dkbmed.com/issues/157).
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
14 Sept 2022
ETI (CFTR Triple Therapy): Clinical Opportunities
The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit?
Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent’s University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast.
Take our post-test (https://elit.dkbmed.com/issues/150/test) to claim CME credits.
Read this podcast's companion newsletter here (https://elit.dkbmed.com/issues/145).
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.4 / 5
5 ratings
Podcast Authority Score: 21 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
29
Social presence
0
YouTube
0
Engagement
31
Contact eCysticFibrosis Review
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of eCysticFibrosis Review?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
